Efficacy of XEN gel stent implantation in patients with glaucoma
Session Details
Session Title: Presented Poster Session: Posterior Segment
Venue: Poster Village: Pod 3
First Author: : D.Wróbel-Dudzińska POLAND
Co Author(s): : E. Kosior-Jarecka J. Jurkowska-Dudzinska D. Pozarowska T. Zarnowski
Abstract Details
Purpose:
To assess the efficacy of XEN implantation in patients with glaucoma in reducing intraocular pressure and medications.
Setting:
This study analyses the clinical outcomes of minimally invasive glaucoma surgery with the XEN gel stent implantation for 14 patients in Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland
Methods:
A prospective study enrolled 14 eyes with 3 medications to control intraocular pressure (IOP) who underwent the XEN gel stent ab interno implantation surgery. Mean age of patients was 66,07±8,18. The main diagnosis was primary open angle glaucoma in 12 cases; pseudoexfoliative glaucoma in 2. Phacoemulsification combined with the XEN gel stent implantation was performed in 5 cases.
Results:
The mean best corrected visual acuity before the surgery was 0,48±0,36 and 0,48±0,39 (p=0,067) 3 months after the surgery.The mean pre-operative IOP was 26,7±6,67mmHg with 3antiglaucoma medications and decreasing to 14,37±4,37mmHg(p=0,017) 1 days after the surgery, after one month the mean IOP was 18,87±5,24 mmHg(p=0,034),and after 3 months 18±5,03mmHg(p=0,042).The number of medication classes reduced from 2.69±0,63 to 1,75±0,50 three months postoperatively(p=0,067).After 3 months 3 patients did not achieve the success defined as IOP⩽18 mm Hg, moreover 5 patients did not achieve 30% reduction of IOP after surgery and required hypotensive medications.
Conclusions:
Our early study suggests that the XEN gel stent implantation reduced intraocular pressure and the long-term commitment to topical glaucoma medications. Well-designed randomized clinical trials are necessary to evaluate the long-term efficacy and late complications of these novel procedures.
Financial Disclosure:
NONE
